tldrdailynews.com logo
Tag

Tirzepatide

All articles tagged with #tirzepatide

GLP-1 Weight Drugs May Dampen Binge Eating Symptoms, Review Finds
health3 days ago

GLP-1 Weight Drugs May Dampen Binge Eating Symptoms, Review Finds

A meta-analysis of 25 RCTs (n=8,069) finds GLP-1 receptor agonists used for weight loss—such as semaglutide, tirzepatide, and liraglutide—also reduce binge eating, loss-of-control eating, and emotional eating beyond weight loss, while dietary restraint tends to rise. Researchers caution that most trials had bias and limited BED-diagnosed samples, and emphasize integrating medication with psychological therapy and social support, plus addressing public-access barriers. More independently funded, long-term studies are needed to confirm clinical utility.

via Neuroscience News|
#binge-eating-disorder#glp-1-receptor-agonists#health
High-Dose GLP-1 Drugs May Dim Joy, Doctors Warn
health3 days ago

High-Dose GLP-1 Drugs May Dim Joy, Doctors Warn

Doctors report three cases of anhedonia (loss of pleasure) in people taking the obese‑treating GLP-1 drug tirzepatide at very high doses (up to 15 mg/week). In all cases, symptoms eased after reducing the dose (and in one case adding an antidepressant), suggesting the effect is dose-related and manageable. The side effect is linked to GLP-1s’ influence on brain reward regions like the ventral tegmental area, though GLP-1 therapies remain associated with reduced depression symptoms overall. Clinicians emphasize monitoring motivation and pleasure during treatment, especially at higher doses, and note that this should not deter indicated use for obesity or type 2 diabetes while remaining vigilant and adjusting dosing as needed.

via Gizmodo|
#adverse-effects#anhedonia#glp-1s
GLP-1 Weight-Loss Revolution: What Science Says About Benefits, Side Effects, and Longevity
health21 days ago

GLP-1 Weight-Loss Revolution: What Science Says About Benefits, Side Effects, and Longevity

Stanford Medicine explains GLP-1 agonists (semaglutide/Ozempic/Wegovy and tirzepatide/Mounjaro/Zepbound) work by slowing gastric emptying and boosting satiety to reduce intake and improve insulin. On average, semaglutide yields about 15% weight loss and tirzepatide about 20%, but responses vary widely and some people lose little weight. Side effects are mainly gastrointestinal and usually transient, though long-term safety data are still evolving. Weight loss typically slows after 4–6 months, with a fuller plateau by 12–18 months; stopping these meds often leads to regain, so many clinicians view GLP-1s as long-term therapies, sometimes alongside lifestyle changes or bariatric surgery. Pediatric use exists but requires caution and specialist guidance. Insurance coverage and cost remain practical hurdles to access.

via Stanford Medicine|
#glp-1#health#obesity
Lilly CEO: GLP-1s May Redefine American Healthcare
business26 days ago

Lilly CEO: GLP-1s May Redefine American Healthcare

Eli Lilly CEO David Ricks says GLP-1 drugs could be more transformative than AI, with strong weight‑loss and health benefits that could curb the roughly $1.4 trillion annual obesity‑related healthcare costs. He notes pricing moves and upcoming Medicare access (around $50 a month starting July) could broaden adoption, while Lilly’s tirzepatide program underscores how GLP‑1 therapies might reshape U.S. healthcare and chronic disease management.

via Yahoo Finance|
#business#eli-lilly#glp-1-therapies
Muscle-Sparing drug combo shows promise during weight loss
science28 days ago

Muscle-Sparing drug combo shows promise during weight loss

A Nature study (EMBRAZE) found that adding apitegromab, an anti-myostatin monoclonal antibody, to tirzepatide helps preserve lean mass while supporting fat loss in adults with overweight or obesity. Over 24 weeks and 102 participants, those on the combo lost less lean mass and about 85% of total weight loss came from fat; adverse events were higher with the combination (76% vs 71%). The trial excluded individuals with diabetes, heart disease, stroke, vascular disorders or active cancer, and the results provide clinical proof of concept for muscle-sparing approaches to GLP-1–based weight loss therapy.

via Yahoo|
#lean-body-mass#myostatin#obesity
Muscle-sparing antibody may lessen lean tissue loss with tirzepatide weight-loss therapy
health1 month ago

Muscle-sparing antibody may lessen lean tissue loss with tirzepatide weight-loss therapy

A small Nature Medicine trial found that adding the monoclonal antibody apitegromab to tirzepatide (a GLP-1–based obesity drug) did not change total weight loss but reduced lean mass loss to about 1.6 kg (3.5 lb), or 14.6% of total weight loss, versus 3.5 kg with tirzepatide plus placebo—a 55% greater retention of lean tissue. Most participants were women; the study was limited in size and duration, so larger, longer trials are needed to assess safety and real-world benefits. Researchers also emphasize maintaining physical activity to help preserve muscle mass during weight-loss therapy.

via The Guardian|
#apitegromab#glp-1-weight-loss-drugs#health
AI Sifts Reddit for Hidden GLP-1 Drug Side Effects
science1 month ago

AI Sifts Reddit for Hidden GLP-1 Drug Side Effects

An AI-assisted analysis of over 410,000 Reddit posts from six years looked for mentions of GLP-1 drugs (semaglutide or tirzepatide). The researchers found signals suggesting potential side effects in reproductive health (e.g., irregular menstrual cycles) and temperature regulation (chills/hot flashes). They emphasize these are not proven effects or a replacement for clinical trials, but suggest online discussions can reveal underreported symptoms worth investigating as GLP-1 therapies become mainstream. Using OpenAI GPT models to scan Reddit enabled rapid signal detection, with findings published in Nature Health.

via ScienceAlert|
#glp-1-drugs#reddit#science
Five-pathway obesity drug outperforms Ozempic in mice, signaling a multi-target therapy future
health2 months ago

Five-pathway obesity drug outperforms Ozempic in mice, signaling a multi-target therapy future

Munich researchers engineered a single molecule that activates five metabolic targets (GLP-1, GIP, plus three internal PPAR switches) with gut-targeted delivery. In obese mice it reduced appetite, body fat, and weight more than semaglutide (Ozempic) and a GLP-1/GIP co-agonist, while also improving blood sugar control and lowering liver fat/inflammation without the usual lanifibranor-side effects; if results translate to humans, this could pave the way for a weekly, five-target obesity therapy, though clinical trials will take years.

via Earth.com|
#gip#glp-1#health
Genes influence GLP-1 weight-loss drug responses and side effects
health3 months ago

Genes influence GLP-1 weight-loss drug responses and side effects

Genetic differences, including a GLP1R variant and a GIPR variant, modestly affect how much weight people lose and their risk of nausea on GLP-1 obesity drugs; the weight-loss difference is small—about 1.7 lb more at eight months for one copy and ~3.3 lb for two copies. A GIPR variant was linked to higher nausea with tirzepatide. Separately, higher GLP-1 doses may confer cardiovascular benefits that seem independent of weight loss, suggesting dosing could optimize heart outcomes; tissue data indicate potential direct cardiac effects, warranting further study.

via Reuters|
#genetics#glp-1#health
DNA Clues Shed Light on Why GLP-1 Weight-Loss Varies
health3 months ago

DNA Clues Shed Light on Why GLP-1 Weight-Loss Varies

A large 23andMe GWAS of 27,885 GLP-1 med users links variants in GLP1R and GIPR to both weight-loss efficacy and nausea risk. A GLP1R missense variant (rs10305420) is associated with about 0.76 kg more weight loss per allele, while GIPR variants predict nausea specifically for tirzepatide (Zepbound/Mounjaro) but not semaglutide. 23andMe’s Total Health service now offers an interactive tool to estimate individual weight loss (roughly 6–20% of starting weight) and side-effect risk, moving toward precision obesity care where genetics is one piece of the puzzle though not the sole determinant.

via Neuroscience News|
#genetics#glp-1#health
Genetic variants forecast GLP-1 weight‑loss response and nausea risk
science3 months ago

Genetic variants forecast GLP-1 weight‑loss response and nausea risk

A large GWAS in 23andMe participants identifies a GLP1R missense variant (rs10305420) linked to greater weight loss from GLP‑1 receptor agonists (~0.76 kg per allele) and links GLP1R and GIPR variants to treatment‑related nausea/vomiting, with a tirzepatide‑specific GIPR signal; replication in All of Us EHR data and integrated predictive models show that combining genetic and non‑genetic factors can stratify patients by efficacy and side‑effect risk, advancing precision obesity treatment.

via Nature|
#gipr#glp1r#obesity
Hormone Therapy May Boost GLP-1 Weight-Loss Drugs in Postmenopausal Women
health3 months ago

Hormone Therapy May Boost GLP-1 Weight-Loss Drugs in Postmenopausal Women

A retrospective study of 120 postmenopausal women found that adding menopausal hormone therapy to tirzepatide led to about 19.2% total body weight loss over roughly 18 months, versus 14% with tirzepatide alone, a statistically significant difference. The study is not randomized and did not distinguish hormone therapy types; researchers say controlled trials are needed to confirm the potential synergy and to explore cardiometabolic effects, building on prior work suggesting similar benefits with other GLP-1 drugs plus hormone therapy.

via ScienceAlert|
#glp-1#health#menopausal-hormone-therapy